Member Info for Dibs61

I think today’s announcement was almost one RNS too far. They’ve already recently given positive update on the digital side. So to say it’s ‘significantly offset’ physical revenues comes across as a bit desperate in view of recent SP drop back.

Totally agree long term this is excellent prospect. But it is LONG term.

I make no bones about it, I think this could well drop back under 10p and it’s at that kind of level I will begin to buy back in. Now is not the time.

And the more the valuation increases, and this stock is clearly undergoing a rerate, the less of an issue any possible dilution would be. But inclined to agree with haggis (I like haggis).

And no way this should be affected by Covid hysteria. AFC are in probably fastest growing industrial sector of the next ten years.

DYOR

Thanks Michael and a Merry Christmas and hopefully a Happier New Year for one and all!

Yes I would like to sincerely echo PhilGekkos sentiments. While the price was dropping in the false vaccine euphoria that Covid was going to disappear in a puff of smoke in the new year I was buying. Buying all the way down to 77p so yes, thank you very much.

As I’ve said before, investing isn’t ‘that’ hard. 1st rule : don’t lose money. 2nd rule : Buy low and sell high.

Sadly so many get it the wrong way round.

Kicks off about it I am NOT ****ing on the vaccine parade BUT the Moderna vaccine is about to be approved and here is the huge caveat. The US government has secured enough doses to vaccinate 3.5m Americans. Or, to put it in stark perspective that’s 1% of the population.

It’s not going to make a scrap of difference to the big picture.

Just remember that when all the trumpeting starts.

And it ain’t me!

Well Axe that’s my thinking too. By saying the first dose is “imminent” and that they’ve stated Q4 trial start. Well, we absolutely can expect another RNS either next week or week after. And that should give this another boost.

We can now safely say that the ‘delay’ (if indeed there was given their stated timeline) was caused by further discussions re trial design etc. No bad thing. Crucial to get it right both from SNG and FDA perspective. This drug may well be earmarked for major use in the States through either a big Pharma partnership or take over. Remember RM has ALWAYS stated the ultimate goal was a partner/licensing deal.

But anyway a lot of nerves have been settled here today!

Bobby - yes that is a possibility. They won’t let a limited spell of lockdown limit their ambitions. Indeed the opposite is likely as they eye up a lot of cheap potential high street sites. I think Escape Hunt will become a common brand on the ‘new post Covid’ high street.

BUT, as you suggest they may not have sufficient short term capital to meet those aims.

So I wait on the sidelines for now.

Yes nozzla. Both CGNR and AAZ have put far too much into this arrangement to be any possibility of pulling out now. AAZ have incorporated this project into their strategic planning for 2021. It is an important way of derisking their ‘jurisdictional spread’ shall we say, given recent events.

And, of course, for CGNR this is truly transformational. On a scale that most investors won’t appreciate fully until this IS £1 and beyond! And I see that target being reached comfortably next year.

https://www.bioworld.com/articles/435669-evoxs-exosome-platform-draws-lilly-in-potential-12b-cns-deal

MIKODX - if I could correct you it’s not true to say SNG001 is applied nasally. It’s not. It is applied via a nebuliser through the mouth.

They’re def NOT similar products. TILs drug treats the nasal tract and SNG001 acts directly into the lung.

I hope both are successful.

Rooky - your last sentence- yes that is absolutely what they need now imo

Would transform the situation here, which is too slow

Brentw1 - thanks for that brilliant explanation of the technical process during an auction.

That’s why this is dropping back. Too early to get back in. We already have T3 restrictions over much of England to be followed by a full lockdown in January/February. If not best case scenario is T3 widespread restrictions. ESC revenues will suffer.

This is fantastic growth prospect. Just not yet. Wait until Q2 2021.

Caribbean - firstly my condolences for the death of your grandma.

I am very confident we are going to see some highly promising drill results. 2.4 will be a distant memory. I actually think SP has held up very well with the combination of delayed results and dilution. Short term target 4.5p

Though I agree newboy I am still confident fast track FDA will drop next week. This will leave us with the juicy prospect of a Christmas/New Year SP rally taking this to new highs.

https://www.investegate.co.uk/reneuron-group-plc--rene-/rns/notification-of-major-holdings/202012180700050839J/

Richard Griffiths has taken 5% stake here. Good endorsement of prospects and assume he did so in the placing.

No. It can’t be without an RNS preceding it.

We’re looking at a SP 56/57p tomorrow if tradegate a reliable indicator. Would be consistent with rises over past few days. If volume stays high can’t see why not.

Interesting. Doesn’t look like the USA (at very least) is going to be seeing the AZN vaccine anytime soon.

I haven’t forgotten the very confident promise of the AZN CEO back in May that the AZN Vaccine would be ready to be rolled out in September.... well it looks like he may have got the month right, just not the year. 2021.